The Committee discusses and makes recommendations on the safety and effectiveness of GSK‘s Biologics License Application (BLA) 125775 (STN 125775/o) for active immunization for the prevention of LRTD caused by respiratory syncytial virus RSV-A and RSV-B subtypes in adults 60 years of age and older in a virtual meeting to be held on March 1 at 8 am. Webcast Link
Protect Your Portfolio Against Market Uncertainty
- Discover companies with rock-solid fundamentals in TipRanks' Smart Value Newsletter.
- Receive undervalued stocks, resilient to market uncertainty, delivered straight to your inbox.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on GSK: